(IN BRIEF) The Institute of Cancer Research has led a study showing that chromosomal instability in circulating tumour cells can predict resistance to cabazitaxel in men with advanced prostate cancer. Using blood samples from more than 200 patients enrolled in … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Blood test developed by ICR researchers may guide treatment decisions in advanced prostate cancer, cabazitaxel, CARD trial, chemotherapy resistance, chromosomal instability, circulating tumour cells, JCI Insight, liquid biopsy, mCRPC, metastatic castration-resistant prostate cancer, oncology biomarkers, personalised cancer treatment, Prostate Cancer Research, Sanofi, The Institute of Cancer Research London
(IN BRIEF) ZEISS has launched its labs@location program in Australia, naming the Walter and Eliza Hall Institute of Medical Research’s Centre for Dynamic Imaging as its first local partner. The collaboration brings ZEISS’ advanced microscopy technologies together with WEHI’s long-standing … Read the full press release
Posted in Business, Electronics & Machinery, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Technology
Tagged advanced imaging, Australia research collaboration, biomedical research, cancer research, Centre for Dynamic Imaging, Disease Research, Dr René Hessling, imaging workflows, infection and immunity, labs@location, lifelong health, microscopy innovation, Professor Kelly Rogers OAM, research infrastructure, scientific collaboration, Walter and Eliza Hall Institute of Medical Research, WEHI, ZEISS, ZEISS Australia and New Zealand, ZEISS Expands Global labs@location Network to Australia Through WEHI Collaboration
(IN BRIEF) The EBRD is providing a €14 million loan to Farmalogist to build a new, energy-efficient logistics centre in Belgrade, with €1.2 million in concessional financing from the Global Environment Fund. The project will centralise and automate operations, significantly … Read the full press release
Posted in Banks, Financial, Industrial, Infrastructure & Utilities, Investment, Pharma & Biotech, Serbia, Technology, Transportation & Logistics, United Kingdom
Tagged automation, Belgrade, CERI, circular economy, Circular Economy Regional Initiative, EBRD, EBRD Backs Circular Economy-Driven Logistics Investment for Farmalogist in the Western Balkans, energy efficiency, European Bank for Reconstruction and Development, Farmalogist, GEF, Global Environment Fund, Green Economy Transition, Janko Radunovic, logistics centre, Matteo Colangeli, pharmaceutical distribution, renewable energy, SERBIA, supply chain modernisation, sustainable logistics
(IN BRIEF) A nationwide retrospective study presented at EACVI 2025 found that AI-derived fractional flow reserve from coronary CT (FFR-CT) is a strong independent predictor of future cardiovascular events in patients undergoing evaluation for suspected stable coronary artery disease. Using … Read the full press release
Posted in Artificial Intelligence (AI), Austria, Business, Education, France, Healthcare, Industrial, Management, Marketing, News, Non Profit, Pharma & Biotech, Science, Technology
Tagged AI-Derived Coronary Flow Assessment Identifies High-Risk Patients in Stable Coronary Artery Disease, artificial intelligence imaging, CAD, cardio-oncology, cardiovascular mortality, CCTA, clinical outcomes, Coronary Artery Disease, coronary computed tomography angiography, CT-derived fractional flow reserve, EACVI 2025, ESC, FFR-CT, FISH&CHIPS study, Jack Bell, myocardial infarction risk, Non-invasive Imaging, prognostic imaging, revascularisation, Timothy Fairbairn, Vienna
(IN BRIEF) A major observational study presented at EACVI 2025 found that valvular heart disease is common in patients with prior cancer diagnoses, with 7.2% showing severe disease on echocardiography. Conditions such as tricuspid and mitral regurgitation and aortic stenosis … Read the full press release
Posted in Artificial Intelligence (AI), Austria, Business, Education, France, Healthcare, Industrial, Management, Marketing, News, Non Profit, Pharma & Biotech, Science, Technology
Tagged anthracyclines, Aortic Stenosis, cancer survivors, cardio-oncology, cardiotoxicity, cardiovascular death, Cardiovascular Imaging, CESAR study, EACVI 2025, echocardiography, ESC, European Association of Cardiovascular Imaging, European Society of Cardiology, Maximilian Autherith, mitral regurgitation, mortality risk, New Research Highlights Need for Regular Cardiac Monitoring as Cancer Survivors Face High Rates of Valvular Heart Disease, survival benefit, tricuspid regurgitation, valve intervention, valvular heart disease, Vienna
(IN BRIEF) Technical University of Munich researchers have found a way to boost oxidase biosensor accuracy from about 50% to 99% by using an alcohol oxidase oxygen scavenger that prevents signal loss, eliminating the need for calibration. The advancement enhances … Read the full press release
Posted in Agriculture, Education, Germany, Healthcare, Management, Pharma & Biotech, Science, Technology
Tagged agriculture nitrogen test, AI health data, AI-Data, alcohol oxidase, and Crop Analysis, biosensor accuracy, biotechnology, Breakthrough at TUM Boosts Oxidase Sensor Performance for Health, creatinine, glucose monitoring, Horizon Europe, Huijie Zhang, lactate, LiveSen-MAP, Mohamed Saadeldin, Nicolas Plumeré, oxidase biosensors, oxygen scavenger, personalised medicine, Science Advances, sustainability, Technical University of Munich, TUM, wearable diagnostics
(IN BRIEF) Novartis announced new MONALEESA pooled analysis results showing that 25% of HR+/HER2- metastatic breast cancer patients treated first-line with Kisqali plus endocrine therapy remained progression-free for four or more years, with a median PFS of 6.8 years. Durable … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Switzerland
Tagged biomarkers, CDK4/6 inhibitor, ctDNA, early breast cancer, endocrine partner therapy, endocrine therapy, ESMO MCBS rating, global oncology research, HR+/HER2- breast cancer, Kisqali demonstrates sustained outcomes across trials as Novartis highlights long-term control and recurrence reduction, Kisqali®, long-term progression-free survival, Luminal A subtype, Mark Rutstein, metastatic breast cancer, MONALEESA trials, NATALEE trial, NCCN Category 1, Novartis, OS benefit, Pedram Razavi, precision oncology, ribociclib, SAN ANTONIO Breast Cancer Symposium SABCS
(IN BRIEF) Empa researcher Robert Zboray has been appointed titular professor at the University of Bern, effective December 1, 2025. Zboray lectures in biomedical engineering and advanced X-ray imaging and leads a research group at Empa’s Center for X-ray Analysis. … Read the full press release
Posted in Artificial Intelligence (AI), Education, Healthcare, Industrial, Pharma & Biotech, Science, Switzerland, Technology, Transportation & Logistics
Tagged 3D tumor imaging, advanced X-ray imaging, AI diagnostics, biomedical engineering, Center for X-ray Analysis, Empa, Empa Imaging and Image Analysis Platform, multi-energy X-ray technology, multimodal imaging, pathology innovation, personalized medicine, Robert Zboray, thyroid cancer, titular professor, Titular professorship awarded to Empa scientist Robert Zboray as research in multimodal X-ray imaging advances, University of Bern
(IN BRIEF) Evotec SE announced that Bayer has initiated a Phase 2 clinical study for BAY 3401016, a Semaphorin-3A-targeting monoclonal antibody being developed as a potential therapeutic option for patients with Alport syndrome. As part of the companies’ kidney disease … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Technology
Tagged Alport syndrome, ASSESS study, BAY 3401016, Bayer, clinical development, COL4A3, COL4A4, COL4A5, end stage renal disease, Evotec, Evotec Announces Phase 2 Advancement of BAY 3401016 for Alport Syndrome in Collaboration with Bayer, milestone payment, monoclonal antibody, phase 2 trial, podocytes, rare kidney disease, Sema3A, Semaphorin-3A
(IN BRIEF) Fresenius’ mAbxience has partnered with HP Inc. to co-develop an AI and digital-twin solution that can model and optimise biopharmaceutical manufacturing. The technology uses real plant data to simulate production scenarios, helping increase reliability, stabilise yields and shorten … Read the full press release
Posted in Artificial Intelligence (AI), Business, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged AI collaboration, AI Collaboration Between mAbxience and HP Targets Smarter, Biopharma Innovation, bioprocess optimisation, biosimilars production, cell culture process, digital transformation, digital twin biomanufacturing, Fresenius, FutureFresenius strategy, HP Inc., industrial AI, León Spain, mAbxience, manufacturing efficiency, monoclonal antibodies, More Predictable Bioprocessing
(IN BRIEF) A new University of Southampton–led human challenge trial has shown that BPZE1, a nasal spray vaccine for whooping cough, can prevent the bacteria from colonising the nose and throat — a first for any whooping cough vaccine. Conducted … Read the full press release
Posted in Business, Education, Environment, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Ashley Dalton, BPZE1, clinical trial, controlled infection model, Diane Gbesemete, human challenge trial, ILiAD Biotechnologies, Marian Knight, nasal spray vaccine, NIHR, NIHR Southampton BRC, NIHR Southampton CRF, PERISCOPE consortium, pertussis, public health, respiratory infections, Robert Read, The Lancet Microbe, UKHSA, University Hospital Southampton, University of Oxford, University of Southampton, University of Southampton research demonstrates strong protection from BPZE1 nasal vaccine against whooping cough spread, vaccine, whooping cough
(IN BRIEF) EIB is providing up to €37.5 million in venture debt to Xeltis as part of a new €50 million financing package that will help bring aXess, the company’s regenerative vascular access conduit, to market. The investment follows excellent … Read the full press release
Posted in Banks, Energy, Gas & Oil, European Union, Financial, Healthcare, Infrastructure & Utilities, Investment, Luxembourg, Netherlands, News, Pharma & Biotech
Tagged Alexander Goemans, aXess, commercialization funding, EIB, Eliane Schutte, end stage renal disease, Endogenous Tissue Restoration, EQT Life Sciences, ETR platform, EU pivotal trial, European Investment Bank, hemodialysis, Invest-NL, InvestEU, LSP Health Economics Fund 2, MedTech innovation, PFAS free polymer technology, regenerative implants, Robert de Groot, US pivotal trial, vascular access conduit, venture-debt financing, Xabg, Xeltis, Xeltis Advances Regenerative Implant Portfolio with Strong Backing from EIB and Existing Investors
(IN BRIEF) GEA and Hovione have expanded their long-term partnership with the introduction of the ConsiGma® CDC Flex, an advanced platform designed to bring new levels of flexibility, efficiency, and usability to continuous direct compression. The system, unveiled at the … Read the full press release
Posted in Business, Electronics & Machinery, Food & Beverage, Germany, Industrial, News, Pharma & Biotech, Technology
Tagged automation, ConsiGma CDC Flex, continuous direct compression, continuous tableting, cost efficiency, CPHI Frankfurt, Filipe Gaspar, GEA, Hovione, Jim Holman, modular blender system, New ConsiGma CDC Flex Platform Expands Continuous Tableting Capabilities Through GEA–Hovione Collaboration, operator safety, oral solid dosage forms, pharmaceutical manufacturing, process flexibility, production throughput, R&D scalability, SimpleCT
(IN BRIEF) Fresenius Kabi has launched its denosumab biosimilars Conexxence® and Bomyntra® across Europe following European Commission approval in July 2025 for all indications of their reference medicines Prolia® and Xgeva®. The products target a range of conditions including osteoporosis, … Read the full press release
Posted in Business, Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged Biosimilar Development, biosimilar portfolio, Bomyntra, bone metastases, Conexxence, denosumab biosimilar, Dr. Sang-Jin Pak, EU approvals, European launch, Fresenius Kabi, Fresenius Kabi Advances Biosimilars Access in Europe with New Approvals for Conexxence and Bomyntra, global healthcare, KabiCare, LUMIADE-3 trial, oncology biosimilars, osteoporosis treatment, patient access, Prolia, RANKL inhibitor, skeletal related events, Xgeva
(IN BRIEF) Researchers at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust have developed AI software that automates the complex interpretation of whole-body diffusion-weighted MRI scans, which are increasingly used to evaluate advanced prostate cancer. The … Read the full press release
Posted in Artificial Intelligence (AI), Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AI MRI prostate cancer, AI-driven MRI software could streamline metastatic tumour evaluation and support next-generation precision oncology, anatomical segmentation, Computer Methods and Programs in Biomedicine, Dr Antonio Candito, Dr Matthew Blackledge, lesion detection, metastatic prostate cancer, NIHR Invention for Innovation, personalised oncology, Physics in Medicine & Biology, precision cancer care, The Institute of Cancer Research London, The Royal Marsden NHS Foundation Trust, tumour burden quantification, WB-DWI, whole-body diffusion-weighted MRI
(IN BRIEF) Novonesis has launched Quara® Supreme, a thermostable enzymatic water-degumming solution developed to improve crude vegetable oil yield without generating free fatty acids. The biosolution enables processors to reduce typical degumming losses by as much as 2%*, while operating … Read the full press release
Posted in Business, Chemicals, Denmark, Germany, Industrial, News, Pharma & Biotech, Science, Technology
Tagged biosolutions innovation, drop-in biosolution, enzymatic degumming, flexible process integration, Hans Ole Klingenberg, no FFA generation, Novonesis, phosphorus reduction, Quara Supreme, refinery efficiency, soybean rapeseed canola oils, thermostable enzyme 85C, Thermostable enzyme from Novonesis boosts refinery efficiency and simplifies water-degumming operations, up to 2 percent extra oil, vegetable oil refining, water degumming yield loss
(IN BRIEF) GEA has launched the LYOVAC®ECO mode to significantly reduce the energy consumption of pharmaceutical freeze-drying systems, achieving validated savings of about 20 percent. The feature improves efficiency by dynamically adjusting condenser temperature and plate valve settings without affecting … Read the full press release
Posted in Business, Electronics & Machinery, Germany, Industrial, News, Pharma & Biotech, Technology
Tagged Add Better label, atmospheric spray drying, dynamic condenser temperature control, energy optimization, energy savings, GEA, GEA Advances Sustainable Pharmaceutical Freeze-Drying with TÜV-Verified LYOVAC ECO Mode, ISO 14021, liquid condenser, LYOAIR cooling system, LYOVAC ECO mode, LYOVAC FCM 500 D, microwave assisted drying, pharmaceutical freeze drying, plate valve control, sustainable processing technologies, Thomas Beutler, TÜV Rheinland
(IN BRIEF) Sandoz has launched Afqlir®, its biosimilar to aflibercept, across Europe following European Commission approval in 2024. Equivalent in efficacy, safety, and pharmacokinetics to Eylea®, Afqlir® provides a lower-cost treatment option for serious retinal diseases such as nAMD, RVO, … Read the full press release
Posted in Business, Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged aflibercept, Afqlir, anti-VEGF market, biologic medicines, biosimilar portfolio, biosimilars, Christophe Delenta, DME, European Commission approval, European Rollout of Afqlir Marks Major Step in Sandoz Expansion Across Anti-VEGF Ophthalmology Market, Eylea, intravitreal injection, mCNV, nAMD, ophthalmology, retinal diseases, RVO, Sandoz, Sustainable Healthcare, vision loss treatment
(IN BRIEF) The Institute of Cancer Research, London, has announced the launch of the £42 million TRANSFORM trial, the UK’s largest prostate cancer screening study in more than 20 years. The first men have now been invited by their GPs … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged 42 million research investment, Black men prostate cancer risk, cancer genetics, Caroline Moore, clinical research, Ealing Community Diagnostic Centre, early diagnosis, fast MRI, genetic saliva test, Hashim Ahmed, Institute of Cancer Research, Institute of Cancer Research Supports Major UK Study Testing Advanced Screening Methods for Prostate Cancer, Lucy Chappell, Mark Emberton, men's health, NHS screening programme, NIHR, prostate cancer screening, Prostate Cancer UK, PSA testing, Rakesh Heer, Rhian Gabe, Ros Eeles, screening inequalities, TRANSFORM trial, UK National Screening Committee, Wes Streeting
(IN BRIEF) AstraZeneca’s Alexion division has received FDA approval for Koselugo (selumetinib) to treat adults with NF1 who have symptomatic, inoperable plexiform neurofibromas. The decision is based on strong results from the Phase III KOMET trial, which showed a 20% … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adult NF1 PN, Alexion, Annette Bakker, ASCO 2025, AstraZeneca, AstraZeneca Expands Koselugo’s Clinical Reach with New US Approval for Adults Living with Inoperable NF1 Plexiform Neurofibromas, Children’s Tumor Foundation, FDA approval, KOMET Phase III trial, Koselugo, Marc Dunoyer, MEK inhibitor, neurofibromatosis type 1, NF1, paediatric NF1 PN, Pierre Wolkenstein, plexiform neurofibromas, PN, rare disease treatment, regulatory approval, selumetinib, The Lancet, tumour response rate
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?